Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Impact of T Cells on Age-related Vascular Dysfunction: A Translational Approach
NCT04344873 · University of Utah · EARLY_PHASE1 · withdrawn · last registry update 2026-01-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “COVID initially delayed plans to begin recruitment of subjects. Subsequently, the departure of a clinical investigator and loss of access to equipment and study subject population resulted in study termination before any subjects were enrolled.” | – | Registry record, University of Utah |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD86 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Donor-derived Mesenchymal Stromal Cells + alemtuzumab (NCT03504241)
- 2026-10-15Results posted on the registry: Rohit Aggarwal, MD, Nintedanib + Placebo (NCT05799755)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Belatacept + methylprednisolone (NCT01790594)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Alemtuzumab + MMF (NCT01436305)
- 2026-09-24Also stopped (terminated): National Institute of Allergy and Infectious Diseases (NIAID), Anti-thymocyte Globulin (Rabbit) + belatacept (NCT01856257)
- 2026-09-10Also stopped (suspended): Leland Metheny, Cyclophosphamide + Fludarabine (NCT06680661)
- 2026-08-31Results posted on the registry: University of Minnesota, abatacept infusion + Placebo group (NCT05822583)
- 2026-08-14Results posted on the registry: University of Texas Southwestern Medical Center, Belatacept (NCT04786067)
- 2026-05-29Results posted on the registry: Beth Israel Deaconess Medical Center, Abatacept (NCT01954979)
- 2026-04-29Results posted on the registry: National Heart, Lung, and Blood Institute (NHLBI), Briquilimab + Filgrastim (NCT06145282)
- 2026-04-03Results posted on the registry: Idelberto Badell, Abatacept 125Mg/Ml Syringe (NCT05975450)
- 2026-01-26Phase 3 first posted: Federal Research Institute of Pediatric Hematology, Oncology and Immunology, Cyclosporine A (CsA) + Sirolimus (NCT07366801)
- 2026-01-23Results posted on the registry: Duke University, Abatacept Injection (NCT03841357)
- 2025-12-10Also stopped (terminated): University Hospital, Grenoble, Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab (NCT05145296)
- 2025-09-09Phase 3 first posted: Coya Therapeutics, COYA 302 + Placebo (NCT07161999)
- 2025-03-30Also stopped (terminated): University of Leeds, Orencia 125 MG Per 1 ML Prefilled Syringe (NCT04261023)
- 2025-03-04Also stopped (terminated): Roswell Park Cancer Institute, Abatacept + Dexamethasone (NCT03457142)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision